Skip to main
FGEN
FGEN logo

FibroGen (FGEN) Stock Forecast & Price Target

FibroGen (FGEN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 15%
Buy 31%
Hold 38%
Sell 8%
Strong Sell 8%

Bulls say

FibroGen Inc. is positioned for a positive financial outlook due to the anticipated rPFS improvements from its therapy FG-3246, which could enhance its competitive stance in the market. The company's financial health is further bolstered by an expected extension of its cash runway and a significant revenue stream from roxadustat, reducing reliance on dilutive capital raises for its R&D efforts. As of the end of the year, FibroGen reported $51 million in cash, in addition to an upcoming $75 million from the sale of FibroGen China to AstraZeneca, strengthening its overall financial standing amidst challenging macroeconomic conditions.

Bears say

FibroGen Inc faces significant risks that could hinder its financial performance, including the potential for failed or inconclusive clinical trials that could stall product development. The company also grapples with the challenge of securing adequate funding, which is crucial for progressing its product candidates and may lead to dilutive capital raises. Additionally, the lack of commercial success in its therapeutic offerings contributes to a negative outlook, exacerbated by concerns surrounding the risk of delisting from stock exchanges.

FibroGen (FGEN) has been analyzed by 13 analysts, with a consensus rating of Hold. 15% of analysts recommend a Strong Buy, 31% recommend Buy, 38% suggest Holding, 8% advise Selling, and 8% predict a Strong Sell.

This aggregate rating is based on analysts' research of FibroGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About FibroGen (FGEN) Forecast

Analysts have given FibroGen (FGEN) a Hold based on their latest research and market trends.

According to 13 analysts, FibroGen (FGEN) has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

FibroGen (FGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.